title: [A study on the relations of soluble interleukin-2 receptor and CD+25 cell with acute graft-versus-host disease].
abstract: OBJECTIVE
  Acute graft-versus-host disease (aGVHD) is one of the major complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Prediction of human aGVHD may be of help in its diagnosis and therapy.
  
  
  METHODS
  22 patients undergoing HSCT were included in this study. After transplantation, serum concentrations of interleukin-6, interleukin-8, tumor necrosis factor-alpha, interferon-gamma and sIL-2R were measured periodically by using enzyme-linked immunosorbent assay. Immune reconstitution of CD(+)(3), CD(+)(4), CD(+)(8), CD(+)(25) and CD(+)(69) cells were analyzed with flow cytometry.
  
  
  RESULTS
  All the patients achieved engraftment. 6 patients developed grade I GVHD and 4 patients developed grade III-IV GVHD. Patients with aGVHD demonstrated significantly higher sIL-2R levels than those without. The peak levels of grade III-IV GVHD were (420.3 +/- 59.8) U/L,and the peak levels of grade I GVHD were (221.5 +/- 38.8) U/L. The increase of sIL-2R level in serum preceded the clinical signs of aGVHD. The maximum levels of sIL-2R correlated significantly with the severity of aGVHD. The increase of CD(+)(25) cells was in accordance with that of sIL-2R.
  
  
  CONCLUSIONS
  Analysis of serum cytokines and immune reconstitution after HSCT may provide predictive value for aGVHD.
authors.affiliation: Department of Hematology, Changhai Hospital, Shanghai 200433, China.
authors.forename: X
authors.initials: X
authors.lastname: Ju
authors.forename: J
authors.initials: J
authors.lastname: Wang
authors.forename: W
authors.initials: W
authors.lastname: Zhang
authors.forename: X
authors.initials: X
authors.lastname: Song
authors.forename: K
authors.initials: K
authors.lastname: Zhou
authors.forename: S
authors.initials: S
authors.lastname: Gong
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D006086:Graft vs Host Disease / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007372:Interferons / Q000276:immunology; D015850:Interleukin-6 / Q000276:immunology; D016209:Interleukin-8 / Q000276:immunology; D007938:Leukemia / Q000628:therapy; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D015850:Interleukin-6; D016209:Interleukin-8; D015375:Receptors, Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D007372:Interferons